99mtc-hexakis-2-methoxy-2-methylpropyl-isonitrile ( tc-sestamibi ) , a new myocardial perfusion radiopharmaceutical , was injected intravenously in 11 patients within 4 hours of the onset of acute myocardial infarction before treatment with intravenous tissue-type plasminogen activator and 6-14 days later .
C0027051
myocardial infarction
C0032143
tissue-type plasminogen activator